The optimal perioperative anticoagulation management in patients on warfarin therapy is poorly defined due to the lack of randomized trials. Because guidelines are heterogeneous, it was hypothesized that “treatment strategies are not uniform in clinical practice”. Between February 2003 and May 2003, a questionnaire with 4 different clinical scenarios was distributed to physicians by e-mail, or direct contact was made by a survey monitor. Two scenarios described the cases of patients with a mechanical heart valve (MHV) in the mitral position, with additional risk factors for a systemic embolism; one undergoing major (scenario 1) and the other minor surgery (scenario 3). Two scenarios described patients with an aortic MHV; one undergoing major (scenario 2) and the other minor (scenario 4) surgery. Different preoperative and postoperative management options were offered. The treatment options for all scenarios were the same. Of the 90 questionnaires distributed, 52 (57.8%) were returned. Hospitalization for full-dose intravenous unfractionated heparin (IV UH) was the most commonly selected strategy in the preoperative phase for scenarios 1 (59%), 2 (42%) and 3 (44%). In scenario 4, 34% chose IV UH. Outpatient, full-dose, subcutaneous UH or low-molecular-weight heparin (LMWH) was the most selected option in the postoperative phase for all scenarios, with the exception of number 4 (52.9% in scenario 1, 34% in scenario 2, 32%, in scenario 3 and 28% in scenario 4). Even among expert clinicians, the management of perioperative anticoagulation is heterogeneous. In particular, the definition of risk categories and the optimal intensity of antithrombotic drugs need to be defined by well-designed prospective studies.

Key Words: Perioperative anticoagulation, mechanical heart valve

INTRODUCTION

The management of the patients with chronic oral anticoagulation during invasive procedures is problematic. Clinical guidelines and reviews have proposed strategies for perioperative anticoagulation in chronically anticoagulated patients.1,6 However, published recommendations are inconsistent, and not based on well-designed clinical trials. Thus, the relative efficacy and safety of different perioperative management strategies remains unknown.

The risk of postoperative bleeding is related to the adequacy of postoperative hemostasis, the type of procedure, age and the presence of malignancy.5 Conversely, the risk of postoperative thromboembolism is determined by the type of procedure, the clinical consequence of recent thromboembolic event, age and the presence of additional thromboembolic risk factors such as malignancy, antiphospholipid syndrome or hered-
The management of patients with mechanical heart valves is of particular concern to treating physicians. There is also considerable controversy and variation in the recommendations for the prevention of thromboembolism in such patients. Kearon and Hirsh suggested that approximately 8 thromboembolic events per 100 patient-years would occur in patients with uncomplicated mechanical valvular prostheses following temporary discontinuation of oral anticoagulants. This risk is much lower than that of patients with a recent episode of deep venous thrombosis (40 cases per hundred patient-years) or arterial thrombosis (15 cases per hundred patient-years). Improvements in prosthetic materials and valve designs have reduced the risk of thromboembolic complications. In the most recent version of the guidelines of the American College of Chest Physicians Consensus Conference on Antithrombotic therapy (ACCP), otherwise healthy patients with a bileaflet or tilting disk valve in the aortic position are considered to be at such low risk of thromboembolism that perioperative anticoagulants are deemed unnecessary when warfarin is interrupted for short time periods. On the contrary, because patients with a mechanical heart valve in the mitral position are thought to be at high risk, full dose UH or LMWH is recommended. Very similar recommendations were previously published by the American College of Cardiology (ACC). However, a distinction in the risk of thromboembolic events between mechanical valves in the aortic and mitral positions when oral anticoagulants are temporarily interrupted has not been universally accepted.

In light of the absence of well-designed prospective studies, and the lack of uniformity among clinical guidelines, the hypothesis that “the perioperative anticoagulation management of patients with mechanical heart valves would be heterogeneous” was tested by conducting a survey.

**MATERIALS AND METHODS**

**Korean survey**

Between February 2003 to May 2003, a questionnaire with 4 different clinical scenarios (Table 1) was distributed to physicians by e-mail, or direct contact was made by a monitor. Only physicians regularly involved in making recommendations about perioperative anticoagulation from university hospitals were chosen. Two scenarios described the patients with a mechanical heart valve (MHV) in the mitral position, with additional risk factors for a systemic embolism: one undergoing major (scenario 1) and the other minor surgery (scenario 3). Two scenarios described patients with an aortic MHV, one undergoing major (scenario 2) and the other undergoing minor (scenario 4) surgery. Different preoperative and postoperative management options were offered. Treatment options for all scenarios were the same. The questionnaire begins with 5 questions aimed at describing the training and role of the participants involved. In particular, participants were asked about the type of specialties of physicians, the frequency with which they make recommendations about perioperative anticoagulation, whether or not they are affiliated with an Anticoagulation Clinic or Anticoagulation Service, and finally, about whether a guideline exists that addresses the management of patients when oral

| Table 1. Clinical Scenarios |
|-----------------------------|
| 1. A 70-year-old woman, with a mechanical mitral valve, chronic atrial fibrillation, and a previous stroke two years ago, is to undergo elective (open) subtotal colectomy for resection of an adenocarcinoma of the colon. |
| 2. A 65-year-old man, with a mechanical bileaflet aortic valve, is to undergo an elective (open) subtotal colectomy for resection of an adenocarcinoma of the colon. He has no other medical problems. |
| 3. A 75-year-old man, with a mechanical mitral valve, a previous stroke 3 years ago and chronic atrial fibrillation, is to undergo an elective bilateral inguinal hernia repair. |
| 4. A 48-year-old woman, with a mechanical bileaflet aortic valve, is to undergo an elective bilateral inguinal hernia repair. She has no other medical problems. |
anticoagulant therapy needs to be interrupted for a procedure exists. All answers were anonymous. The first scenario described “a 70-year-old woman, with a mechanical mitral valve, chronic atrial fibrillation, and a previous stroke two years earlier, who was to undergo an elective (open) subtotal colectomy for resection of an adenocarcinoma of the colon”. The second scenario described “a 65-year-old man, with a mechanical bileaflet aortic valve, who was to undergo an elective (open) subtotal colectomy for resection of an adenocarcinoma of the colon, but had no other medical problems”. The third scenario described “a 75-year-old man, with a mechanical mitral valve, a previous stroke 3 years earlier and chronic atrial fibrillation, who was to undergo an elective bilateral inguinal hernia repair”. The fourth scenario described “a 48-year-old woman, with a mechanical bileaflet aortic valve, who was to undergo an elective bilateral inguinal hernia repair but had no other medical problems”. For each of the 4 scenarios presented, 4 options were proposed for the preoperative management and 5 or the postoperative management of the patients. The anticoagulation options are presented in Table 2.

### Table 2. Anticoagulation Options

| Preoperative options                                                                 |
|--------------------------------------------------------------------------------------|
| (A) Admit to hospital 2 to 4 days preop for full-dose heparin                        |
| (B) Outpatient full-dose SC heparin or LMWH                                         |
| (C) Nothing else other than holding warfarin preoperatively                         |
| (D) Another anticoagulation strategy                                                |

| Postoperative options                                                               |
|--------------------------------------------------------------------------------------|
| (A) Full-dose in-hospital IV heparin until INR therapeutic                           |
| (B) Full-dose SC heparin or LMWH until INR therapeutics                             |
| (C) Low-dose in-hospital or outpatient SC heparin or LMWH until INR therapeutics    |
| (D) Nothing else other than re-starting warfarin postoperatively                    |
| (E) Another anticoagulation strategy                                                |

RESULTS

Of the 90 questionnaires distributed, 52 (57.8%) were returned. Of the 52 physicians responding to the questionnaire, cardiologists were the best represented (n=21, 41.2%), followed by hematologists (n=13, 25%), cardiac or vascular surgeons (n=12, 23.5%) and internists (n=3, 5.9%). Forty-one of the participants returning the questionnaire (78.5%) were affiliated with an Anticoagulation Clinic or an Anticoagulation Service. Of these, 35 (83.3%) reported that they used local guidelines to decide upon the perioperative management strategy when oral anticoagulant therapy was temporarily discontinued.

The results from the survey are shown in Fig. 1. The first scenario described a patient with a high thromboembolic risk undergoing a surgical procedure considered high risk for both thrombotic and hemorrhagic complications. Admission to hospital for full-dose IV UH was the most frequently selected anticoagulation option for preoperative anticoagulation (n=30, 58.8%), followed by “outpatient full-dose subcutaneous (SC) UH or LMWH” (n=17, 33.3%) and “nothing else other than holding warfarin” (n=3, 5.9%). One physician selected “low-dose subcutaneous UH/LMWH”. For the postoperative management, “full-dose SC
UH or LMWH” was the most frequently selected anticoagulation option (n=27, 52.9%), followed by “full-dose intravenous UH” (n=17, 33.3%). Six physicians (11.8%) selected “low-dose SC UH or LMWH” and one “nothing else other than re-starting warfarin” after the operation. No physician selected an alternative anticoagulation strategy.

The second scenario described a patient at low risk of thromboembolic events, according to the last ACCP guidelines, undergoing a surgical procedure considered high risk for both thrombotic and hemorrhagic complications. For the preoperative management, admission of intravenous full-dose UH (n=21, 42%) and full-dose LMWH (n=21, 42%) were the two most frequently selected anticoagulation options, followed by “nothing else other than holding warfarin” (n=5, 10%). Three physicians selected outpatient low-dose SC UH and one did not respond. For the postoperative management, both full-dose SC and low-dose UH or LMWH were the two most frequently selected anticoagulation options (n=17, 34%), followed by full-dose intravenous UH (n=14, 28%). Two physicians (4%) selected nothing else other than re-starting warfarin after the operation and one did not respond.

The third scenario described a man at high risk for thromboembolic complications undergoing a low risk surgical procedure. For the preoperative management, 22 participants (44%) selected intravenous full-dose UH (n=22, 44%), followed by full-dose LMWH (n=21, 42%) and nothing else other than holding warfarin (n=5, 10%); two respondents chose low-dose SC UH and one did not respond. For the postoperative management, hospitalization for intravenous full-dose UH (n=16, 32%) and full-dose SC or LMWH (n=16, 32%) and low-dose SC or LMWH (n=15, 30%) were the most frequently selected anticoagulation options. Three physicians (6%) selected nothing else other than re-starting warfarin postoperatively.

The fourth scenario described a woman at low embolic risk, according to the ACCP guidelines, undergoing a low risk surgical procedure. For the preoperative management, outpatient full-dose LMWH (n=24, 48%) was the most frequently selected anticoagulation option, followed by administered full dose subcutaneous UH (n=17, 34%) and nothing else other than holding warfarin (n=6, 12%). Three physicians selected outpatient low-dose subcutaneous UH and one did not respond.

For the postoperative management, 17 participants (34%) selected low-dose subcutaneous UH or LMWH, followed by full-dose subcutaneous UH or LMWH (n=14, 28%), and full-dose intravenous UH (n=12, 24%). Seven physicians (14%) indicated they would simply reintroduce warfarin without administering any additional antithrombotic treatment.

The preoperative and postoperative choices for each scenario were compared with the results from a 1997 distribution of this survey to Canadian providers (Fig. 2). Compared to the Canadian physicians, the Korean physicians chose LMWH...
DISCUSSION

In this survey, the physician preferences for the perioperative anticoagulation management of patients with mechanical heart valves were investigated. Three main issues were raised by our results. (1) Guidelines suggesting patients with a mechanical aortic valve do not need any perioperative anticoagulation are not universally accepted. (2) There is no clear consensus on the peri-operative management of patients receiving oral anticoagulant treatment. (3) LMWH has been increasingly accepted as a perioperative anticoagulant for patients whose oral anticoagulant therapy must be interrupted.

In recent years, long-term follow up studies have shown that patients with a bileaflet valve (St. Jude Medical or Caromedics) or tilting disk valve (Medtronic-Hall) in the aortic position, and who were in a normal sinus rhythm and have a left atrium of normal size, were at low risk of a systemic embolism, so a lower INR range, between 2.0 and 3.0, is now recommended. However, whether this finding implies a lower risk of a systemic embolism during the short intervals when warfarin has been discontinued needs to be confirmed by well-designed prospective studies.

The answers to our questionnaire revealed a substantial variability in the choice between full and low dose UH or LMWH in both the high and low risk situations. Intravenous full dose heparin was the most frequently selected anticoagulant option, especially in patients with a very high thrombotic risk: 58.8% of participants prescribed full dose UH in the preoperative phase for patients with a mitral valve prosthesis and history of stroke. Conversely, the responses for patients with lower thrombotic risk were less uniform. In
the preoperative phase, for a patient with a mechanical aortic valve and no concomitant thrombotic risk factor, 34% of participants prescribed full-dose UH, whereas 48% prescribed LMWH and 18% no or lower dose heparin until restarting warfarin postoperatively. For all four scenarios, the rate of participants selecting full-dose intravenous UH decreased from the preoperative to the postoperative phases, from 58.8 to 33.3% in the first scenario, 42 to 28% in the second, 44 to 32% in the third, and from 34 to 24% in the forth. Apparently, when warfarin is reintroduced many physicians feel comfortable in administering subcutaneous LMWH/UH instead of intravenous full-dose UH until the INR reaches a therapeutic range. It is possible they consider this strategy to have a lower bleeding risk than IV UH during the postoperative period.

Although full-dose intravenous UH is still indicated by clinical guidelines,2,3,5 LMWH is gradually taking the place of UH in many clinical settings. This acceptance is justified by the results obtained in many trials comparing UH and LMWH for the treatment of venous thromboembolism and acute coronary syndromes.14 Although, evidence suggests that LMWH has comparable clinical efficacy and better cost-effectiveness than intravenous UH as a perioperative anticoagulant.15-17 However, because the published experience in this area consists of small uncontrolled cohort studies,18-24 some physicians are still reluctant to use LMWH, despite its advantages over unfractionated intravenous UH as a perioperative anticoagulant.

The results of our survey are likely to be relevant. Although, the answers were received from only a small number of physicians, with most regularly involved in making recommendations about perioperative anticoagulation in their hospitals, and many involved directly in the local production of clinical guidelines for this purpose. Thus, the results of our survey probably accurately represent the Korean practice patterns.

In conclusion, there is still uncertainty on the optimal perioperative management of chronic anticoagulation patients having mechanical heart valves. Prospective clinical trials will be required to better guide clinicians in their choice of the intensity and type of perioperative antithrombotic strategies according to the thrombotic risk.

ACKNOWLEDGEMENTS

We are indebted to Dr. Jim Douketis for his invaluable help in the design of the questionnaires, and to Ms. Soo Jung Kim for her great support as a survey monitor. We also thank the physicians of the Hematology and Oncology Group in Seoul (HOGS) for their participation.

REFERENCES

1. Kearon C. Perioperative management of long-term anticoagulation. Semin Thromb Haemost 1998;24 Suppl 1:77-83.
2. Bonow RO, Carabello B, de Leon AC Jr, Edmunds LH Jr, Federly BJ, Fareed MD, et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 1998;98:1949-84.
3. Ansell J, Hirsh J, Dalen J, Bussy H, Anderson D, Poller L, et al. Managing oral anticoagulant therapy. Chest 2001;119:22S-38S.
4. Douketis JD. Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians. Thromb Res 2003;108:3-13.
5. Baudo F, Mostarda G, Boniardi M, et al. The management of patients on long term oral anticoagulant therapy undergoing surgery. Haematologica 2002;87 Suppl 2:48-50.
6. Prisco D, Barcellona D, Baudo F, Berretini M, Cianarella N, Cosni B, et al. A guide to oral anticoagulant treatment. Recommendations of the Italian Federation of Anticoagulation Clinics (FCSA). Haematologica 2003;88 Suppl 2:39-41.
7. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997;336:1506-11.
8. Turpie AGG, Ageno W. Antithrombotic therapy after heart valve replacement. In: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ ed. Evidence based cardiology. Second Edition. London: BMJ Books; 2003. p.832-6.
9. Douketis JD, Crowther MA, Cherian SS, Kearon CB. Physician preferences for perioperative anticoagulation in patients with a mechanical heart valve who are undergoing elective noncardiac surgery. Chest 1999;116:1240-46.
10. Acar J, Iung B, Boissel JP, Samama MM, Michel PL,
11. Horstkotte D, Schulte HD, Birks W, Strauer BE. Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude Medical Prosthesis. J Thorac Cardiovasc Surg 1994;107:1136-45.

12. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AGG. Antithrombotic therapy in patients with mechanical or biological prosthetic heart valves. Chest 2001;119:2208-75.

13. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-8.

14. Spyropoulos AC, Turpie AGG, Dunn A, Spandorfer J, and the Regimen Investigators. Clinical outcomes with the use of unfractionated heparin or low-molecular-weight heparin as perioperative bridging therapy in patients on long-term oral anticoagulants: Rationale, objectives, and design of a large, long-term study (REGIMEN).[abstract] Thromb Haemost 2003 Suppl poster #1858.

15. Garcia D, Rich JS, Libby E. Bridging therapy for mechanical heart valves: a model comparing unfractionated and low-molecular-weight heparin.[abstract] Thromb Haemost 2003 Suppl poster #1880.

16. Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Health care costs and clinical outcomes in patients on chronic oral anticoagulation undergoing perioperative bridging with low-molecular-weight heparin vs. unfractionated heparin.[abstract] Thromb Haemost 2001 Suppl poster #1936.

17. Johnson J, Turpie AGG. Temporary discontinuation of oral anticoagulants: role of low molecular weight heparin.[abstract] Thromb Haemost 2001 Suppl poster #2323.

18. Tinmouth A, Kovacs MJ, Cruickshank M, Morrow BH, Moore PM. Outpatient peri-operative and peri-procedure treatment with dalteparin for chronically anticoagulated patients at high risk for thromboembolic complications.[abstract] Thromb Haemost 1999;82 Suppl poster #662.

19. Akins CW. Long term results with the Medtronic-Hall valvular prosthesis. Ann Thorac Surg 1996;61:806-13.

20. Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 1999; 84:478-80.

21. Arizo A, Casais P, Mescengieser SS, Sanchez Luceros A, Hendler M, Lazzari MA. Prospective study of the use of low molecular weight heparin vs unfractionated heparin as bridging therapy for invasive procedures in patients anticoagulated with acenocoumarol.[abstract] Thromb Haemost 2001 Suppl C#3646.

22. Jenkins S, Beaton K, Hart K, Yeo EL. Outpatient reversal of oral anticoagulation with low molecular weight heparin. A pilot study.[abstract] Thromb Haemost 2001 Suppl poster #1421.

23. Ferreira I, Dos L, Tornos P, Nicolau I, Permanyer-Miralda G, Soler-Soler J. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocoumarol. Heart 2003;89:527-30.

24. Kovacs MJ, Kahn S, Solomos S, Anderson D, Desjardins L, Kearon C, et al. Prospective multicenter trial of bridging therapy with dalteparin for patients who require temporary discontinuation of OAT with prosthetic heart valves or high risk atrial fibrillation. [abstract] Blood 2002;100 Suppl.1449a.